FMR LLC boosts disclosure: PHARMA COMPANY NV (NAMS) 8.77M shares reported

Rhea-AI Filing Summary

FMR LLC files an amendment to Schedule 13G reporting beneficial ownership of 8,765,811 shares of PHARMA COMPANY NV common stock. The filing states FMR LLC holds 8,765,811 shares, representing 7.6% of the class, with sole dispositive power and no shared voting power reported. The amendment notes related power-of-attorney authority and references Exhibit 99 and an Exhibit 24 power of attorney.

Insights

Corporate Governance Analyst

Large passive holding reported by an institutional investor; disclosure is routine.

FMR LLC is disclosed as beneficial owner of 8,765,811 shares or 7.6% of PHARMA COMPANY NV common stock, with sole dispositive power shown. Schedule 13G/A amendments are typical when ownership or administrative details change.

Material impact depends on voting intentions and any changes in holdings; subsequent filings would show trading activity or shifts in percent ownership.

Key Figures

Shares beneficially owned: 8,765,811 shares Percent of class: 7.6% Sole dispositive power: 8,765,811 shares +1 more

4 metrics

Shares beneficially owned 8,765,811 shares Amount reported by FMR LLC on Schedule 13G/A

Percent of class 7.6% Percent of common stock represented by the reported shares

Sole dispositive power 8,765,811 shares Sole power to dispose or direct disposition as reported

Shared voting power 0.00 Shared voting power reported on the cover page

Key Terms

Schedule 13G/A, beneficial ownership, dispositive power, Exhibit 99

4 terms

Schedule 13G/A regulatory

"Amendment to Schedule 13G reporting beneficial ownership"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

beneficial ownership financial

"Amount beneficially owned: 8765811.00 (b) Percent of class: 7.6 %"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

dispositive power regulatory

"Sole power to dispose or to direct the disposition of: 8765811.00"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

Exhibit 99 legal

"Please see Exhibit 99 for 13d-1(k) (1) agreement."

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

NEWAMSTERDAM PHARMA COMPANY NV

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

N62509109

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): N62509109

1

Names of Reporting Persons

FMR LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 8,755,902.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 8,765,811.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

8,765,811.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.6 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP Number(s): N62509109

1

Names of Reporting Persons

Abigail P. Johnson

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 8,765,811.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

8,765,811.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.6 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: NEWAMSTERDAM PHARMA COMPANY NV
(b)	Address of issuer's principal executive offices: GOOIMEER 2-35,NARRDEN,P7,1411 DC
Item 2.
(a)	Name of person filing: FMR LLC
(b)	Address or principal business office or, if none, residence: 245 Summer Street, Boston, Massachusetts 02210
(c)	Citizenship: Not applicable
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.: N62509109
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 8765811.00
(b)	Percent of class: 7.6 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page.
	(ii) Shared power to vote or to direct the vote: 0.00
	(iii) Sole power to dispose or to direct the disposition of: 8765811.00
	(iv) Shared power to dispose or to direct the disposition of: 0.00
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of NEWAMSTERDAM PHARMA COMPANY NV. No one other person's interest in the COMMON STOCK of NEWAMSTERDAM PHARMA COMPANY NV is more than five percent of the total outstanding COMMON STOCK.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See attached Exhibit 99.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

FMR LLC

Signature:	Richard Bourgelas
Name/Title:	Duly authorized under Power of Attorney effective as of April 13, 2026, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
Date:	05/05/2026

Abigail P. Johnson

Signature:	Richard Bourgelas
Name/Title:	Duly authorized under Power of Attorney effective as of April 13, 2026, by and on behalf of Abigail P. Johnson*
Date:	05/05/2026

Comments accompanying signature: *This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on April 29,2026, accession number: 0000315066-26-000738.

Exhibit Information

Please see Exhibit 99 for 13d-1(k) (1) agreement.

FAQ

What does FMR LLC report owning in PHARMA COMPANY NV (NAMS)?

FMR LLC reports beneficial ownership of 8,765,811 shares, equal to 7.6% of the common stock. The filing lists sole dispositive power of 8,765,811 shares and no shared voting power in the covered class.

Does the Schedule 13G/A indicate FMR LLC controls voting of the shares?

The filing reports sole dispositive power for 8,765,811 shares and shows 0.00 shared voting power. It does not state that FMR LLC has sole voting power over the shares in the cover responses referenced.

Are any other persons reported as holding more than 5% for PHARMA COMPANY NV?

The amendment states one or more other persons may have rights to dividends or sale proceeds, but explicitly says no other person's interest exceeds 5% of the total outstanding common stock.

What exhibits or authorizations accompany the 13G/A amendment?

The filing references Exhibit 99 for a 13d-1(k)(1) agreement and incorporates a power of attorney via Exhibit 24, referenced with an accession linkage in the signatures section.

When was the amendment signed and who signed on behalf of FMR LLC?

Signatures show Richard Bourgelas signed as duly authorized under a power of attorney effective April 13, 2026, with signature dates of 05/05/2026 for filings on behalf of both FMR LLC and Abigail P. Johnson.